FEV1/FVC fixed ratio again!

Chest

Volumn 139, Issue 5, 2011, Pages 1252-1253

  Fabbri, Leonardo M ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; CRITERION VARIABLE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH CARE PRACTICE; LETTER; LUNG FUNCTION TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 79955775741     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-3148     Document Type: Letter

References (18)

1. 1/FVC <0.70 to detect airway obstruction? No. Chest. 2010;138(5):1037-1040.
2. 1/FVC <0.70 to detect airway obstruction? Yes. Chest. 2010;138(5):1040-1042.
3. Fabbri LM, Boschetto P, Mapp CE; Global Initiative for Chronic Obstructive Lung Disease; Global Initiative for Asthma Management and Prevention. COPD guidelines: the important thing is not to stop questioning. Am J Respir Crit Care Med. 2007;176(6):527-528.
4. Enright PL. Are GOLDen slumbers drug induced? Am J Respir Crit Care Med. 2008;177(6):1291.
5. Fabbri LM, Boschetto P, Mapp CE. Time to wake up! Am J Respir Crit Care Med. 2008;177:1291-1292.
6. Rabe KF, Hurd S, Anzueto A, et al; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532-555. (Pubitemid 47403272)
7. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. National Clinical Guideline Centre (2010). NICE Web site. http://guidance.nice.org.uk/CG101/Guidance/pdf/ English. Accessed June 28, 2010.
8. The Global Initiative for Chronic Obstructive Lung Disease (GOLD). GOLD Web site. www.goldcopd.org. Accessed January 2011.
9. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272(19):1497-1505.
10. Wise RA, Kanner RE, Lindgren P, et al; Lung Health Study Research Group. The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD: the Lung Health Study. Chest. 2003;124(2):449-458.
11. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58(5):399-404. (Pubitemid 36560942)
12. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2006;61(1):91. (Pubitemid 43106987)
13. Calverley PM, Kuna P, Monsó E, et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir Med. 2010;104(12):1858-1868.
14. Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010;362(3):217-227.
15. Quanjer PH, Enright PL, Miller MR, et al; Pulmonaria Group. Open letter: the need to change the method for defining mild airway obstruction. Prim Care Respir J. 2010;19(3):288-291.
16. Self-plagiarism: unintentional, harmless, or fraud? Lancet. 2009;374(9691):664.
17. Decramer M, Rutten-van Mölken M, Dekhuijzen PNR, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005;365(9470):1552-1560. (Pubitemid 40615404)
18. Santayana G. Life of Reason: I. Reason in Common Sense. London, England: Archibald Constable; 1906.